HIMSFriday, 12 Jun 2026
The peptide narrative meets its first scientific pushback
The 'peptide narrative' behind the recent rebound has met its first pushback on scientific evidence. On 11 Jun Nature questioned the science behind peptides, pointing to scant evidence that they work in humans. On 12 Jun Pharmacy Times listed the specific peptides the FDA plans to clear. Opportunity and evidence risk are two sides of the same coin.
Key points
- A Nature article on 11 Jun, asking whether the peptide craze has a scientific basis, took direct aim at viral peptides such as BPC-157, TB-500 and MOTS-c. Animal studies look promising, but 'evidence of efficacy in humans is scarce', and this is currently a 'completely unregulated industry' (vials are labelled 'for research use only').
- Global monthly searches for 'peptide' surged from about 1.3 million in 2024 to about 8 million in 2026, driven purely by social media influencers rather than clinical data.
- Former FDA official Peter Lurie is concerned about the safety of authorising pharmacies to compound these substances in bulk.
- The case for re-rating HIMS as a platform (a new CMO who is a peptide specialist, Canaccord's estimate of a $20 billion TAM) rests on the assumption that 'peptides are the next growth engine'. With a top journal pointing to an evidence gap, the narrative carries tail risk of being disproved or hit by tighter regulation.
- On 12 Jun Pharmacy Times listed the peptides the FDA plans to bring back within the scope of 503A compounding: BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV and MOTS-c.
- Regulatory clearance opens up commercial room, but thin clinical evidence means compliance and liability risks come with it.
Catalysts to watch
- The FDA plans to let 11 peptides back within the scope of 503A compounding, a category telehealth platforms may list in future
Risks
- Evidence risk: Nature, a top journal, has highlighted the gap in evidence of efficacy in humans, so the peptide narrative risks being disproved
- Tail risk of tighter regulation: peptides are currently a 'completely unregulated industry', and a former FDA official has voiced concern publicly
- Compliance and liability risk: thin clinical evidence means legal liability risk once products are listed
- Valuation rests on a weak narrative: the recent rebound relied on peptides, the Novo partnership rumour and the new CMO, but the scientific foundation is more fragile than market sentiment
A brief is a lead for our research, not a verified conclusion or advice.